^
    2d
    SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (clinicaltrials.gov)
    P2, N=51, Recruiting, First Affiliated Hospital of Zhejiang University | N=102 --> 51
    Enrollment change • Mismatch repair • pMMR
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab)
    2d
    Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (clinicaltrials.gov)
    P3, N=895, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • oxaliplatin • levoleucovorin calcium
    2d
    REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma (2024-516709-22-00)
    P2/3, N=94, Recruiting, Centre Hospitalier Regional Universitaire | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • cyclophosphamide • Stivarga (regorafenib) • oxaliplatin • irinotecan • aspirin
    2d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=184, Recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • pumitamig (BNT327)
    2d
    Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    2d
    Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients. (PubMed, Sci Rep)
    To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables earlier prediction of treatment response and detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to profile tumor samples from the KeyLargo study, a phase II trial in which metastatic esophagogastric cancer (mEGC) patients received capecitabine, oxaliplatin, and pembrolizumab. Molecular progression (ctDNA increase) preceded imaging-derived progression by a median lead time of 65 days. These results suggest that ultra-sensitive liquid biopsy approaches could improve treatment decision-making for mEGC patients receiving chemotherapy and immunotherapy.
    Journal • Circulating tumor DNA
    |
    NeXT Personal™
    |
    Keytruda (pembrolizumab) • capecitabine • oxaliplatin
    3d
    A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (clinicaltrials.gov)
    P2/3, N=680, Not yet recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
    New P2/3 trial
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin • Tabosun (ipilimumab N01 injection)
    5d
    A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladder sparing curative treatment for muscle invasive bladder cancer: the CRIMI study (2023-509460-19-00)
    P1/2, N=50, Recruiting, Amsterdam UMC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine • mitomycin
    5d
    TESAR: Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers (clinicaltrials.gov)
    P3, N=302, Recruiting, Amsterdam UMC, location VUmc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine
    6d
    PARC: Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, EBG MedAustron GmbH | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel
    6d
    EVOLVE-BDT: Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (clinicaltrials.gov)
    P2, N=700, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jun 2028 --> Jun 2031 | Trial primary completion date: Jun 2028 --> Jun 2031
    Trial completion date • Trial primary completion date
    |
    everolimus • capecitabine • Verzenio (abemaciclib)